Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Pharma 50: Here’s how the world’s largest pharma companies are doing

By Chris Newmarker | May 12, 2021

Pharma 50 performanceThe global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead.

That’s one of the big takeaways from Drug Discovery & Development’s inaugural Pharma 50, a compilation of data on the largest pharma companies in the world. (Browse data on all 50 companies here.)

Overall, the 50 largest pharma companies brought in $851 billion in sales in 2020. Pharma companies also overcame COVID-19-related clinical trial disruption and staffing hurdles, driving unprecedented R&D advances to introduce novel vaccines and therapies to battle the pandemic. The resulting shift in public perception could benefit the industry for years to come.

One of the most notable achievements involved the mRNA vaccines from Pfizer/BioNTech and Moderna, according to analyst Mani Foroohar at SVB Leerink.

Other achievements, according to Foroohar, include Novartis’ Zolgensma treatment for spinal muscular atrophy (SMA) — a rare and sometimes fatal genetic disease in children.

“This is graduation day,” Foroohar said. “After 10 to 20 years of preparation and investment, genetic medicines are ready for prime time on a commercial basis.”

Here is how 10 of the largest pharmaceutical companies performed in 2020. (Check out all 50 companies here.)

Company 2020 Revenue Change (%) 
Sinopharm (pharmaceutical distribution segment) +3.25%
Roche Pharmaceuticals (division of Roche Group) –4.17%
Novartis +2.56%
Merck +2.46%
Janssen (Johnson & Johnson’s pharmaceutical segment) +8.00%
GlaxoSmithKline (GSK) +1.02%
Pfizer +1.79%
Sanofi –0.24%
AstraZeneca +9.16%
Gilead Sciences +9.98%
TOTAL –3.41%

* Note: Bristol Myers Squibb and AbbVie are left off the list because major acquisitions greatly increased 2020 revenue.

The Pharma 50 project was a team effort including pharma editor Brian Buntz and executive editor Chris Newmarker. Senior editor Danielle Kirsh assisted with company descriptions. 


Filed Under: Drug Discovery and Development
Tagged With: AstraZeneca, Gilead Sciences, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Novartis, Pfizer, Pharma 50, Roche, Sanofi, Sinopharm
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Portrait photo of Cardinal Health CFO and soon-to-be CEO Jason Hollar
Cardinal Health’s CFO to move up to corner office
CNS
The CNS drug development drum beat is getting louder
DeepMind
7 ways DeepMind’s AlphaFold is being used in life sciences
Biomarker
Bioanalytical method development and validation using Quanterix’s Simoa platform 

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50